JPMorgan Chase Financial Company LLC, a wholly owned subsidiary of JPMorgan Chase & Co., has announced the issuance of Callable Contingent Interest Notes linked to the lesser performing of the S&P 500 Index and the SPDR S&P Biotech ETF, with a due date of July 22, 2027. The notes, which are designed for investors seeking contingent interest payments based on the performance of the underlying indices, are unsecured and unsubordinated obligations guaranteed by JPMorgan Chase & Co. The notes may be redeemed early at JPMorgan's discretion on any Interest Payment Date, with the earliest possible redemption date being January 24, 2025. The notes are expected to price on or about July 19, 2024, with a settlement date on or about July 24, 2024. The notes carry risks, including...Show More

JPMorgan Chase Financial Company LLC, a wholly owned subsidiary of JPMorgan Chase & Co., has announced the issuance of Callable Contingent Interest Notes linked to the lesser performing of the S&P 500 Index and the SPDR S&P Biotech ETF, with a due date of July 22, 2027. The notes, which are designed for investors seeking contingent interest payments based on the performance of the underlying indices, are unsecured and unsubordinated obligations guaranteed by JPMorgan Chase & Co. The notes may be redeemed early at JPMorgan's discretion on any Interest Payment Date, with the earliest possible redemption date being January 24, 2025. The notes are expected to price on or about July 19, 2024, with a settlement date on or about July 24, 2024. The notes carry risks, including the potential loss of principal and the possibility that no contingent interest payments will be made. The offering is subject to a pricing supplement, and the notes are not bank deposits, nor are they insured by the FDIC or any other governmental agency. The estimated value of the notes at the time of pricing will be provided in the pricing supplement and will not be less than $940.00 per $1,000 principal amount note. The notes are not designed to be short-term trading instruments, and investors should be prepared to hold them until maturity.